相关实验视频
Updated: Jul 4, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
21.9K
缺血性中风的血栓溶解尽管有直接的口服抗凝药
Jan C Purrucker1, Thomas R Meinel2, Duncan Wilson3
1Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany jan.purrucker@med.uni-heidelberg.de.
Stroke and vascular neurology
|January 31, 2024
概括
尽管目前的指导方针,静脉血栓溶解可能对最近服用直接口服抗凝剂 (DOAC) 的患者是安全的. 新的研究表明,即使在最近服用DOAC时,血栓溶解也是安全的,这挑战了现有的建议.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 目前的美国和欧洲指导方针对最近 (48小时内) 服用直接口服抗凝剂 (DOAC) 的患者进行静脉内血栓溶解是禁忌的.
- 这一建议是基于对增加出血风险的担忧.
- 现有的实验数据和新兴的观察研究要求重新评估这一指南.
研究的目的:
- 讨论关于最近直接服用口服抗凝剂 (DOAC) 的患者静脉血栓溶解安全性的现有证据.
- 分析新观察数据的含义,这些数据表明安全性.
- 探索临床决策的实际后果.
主要方法:
- 审查来自美国和欧洲的当前临床指南.
- 对最近服用DOAC的患者血栓溶解的三项近期观察研究的分析.
- 讨论支持实验数据的讨论.
主要成果:
- 三项观察性研究表明,静脉输血栓溶解在最近直接服用口服抗凝剂 (DOAC) 的患者中是安全的.
- 这些发现挑战了当前的指导方针建议.
- 结果与之前支持安全性的实验数据保持一致.
结论:
- 目前的指导方针可能需要修订关于直接口服抗凝剂 (DOAC) 患者的血栓溶解.
- 新出现的证据表明,即使最近使用了DOAC,也有可能进行安全的血栓溶解.
- 进一步的研究和指导方针更新是必要的,以澄清临床实践.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Disorders of Hemostasis
915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915

